Viral hepatitis: Review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV

Current Rheumatology Reports

Volumn 15, Issue 4, 2013, Pages

  Vassilopoulos, Dimitrios ^a   Calabrese, Leonard H ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Abatacept; Anti tumor necrosis factor agents; Arthritis; Biological agents; Cryoglobulinemic vasculitis; Disease modifying anti rheumatic drugs; DMARDs; HBV; HCV; Hepatitis B virus; Hepatitis C virus; Interferon a; Protease inhibitors; Rheumatoid arthritis; Ribavirin; Rituximab; Therapy; Viral hepatitis

Indexed keywords

ABATACEPT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; METHOTREXATE; PEGINTERFERON ALPHA; RIBAVIRIN; RITUXIMAB; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALGORITHM; ANCA ASSOCIATED VASCULITIS; ARTHRITIS; ARTICLE; ASYMPTOMATIC INFECTION; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC ARTHRITIS; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LOW DRUG DOSE; LYMPHOMA; MONOTHERAPY; NONHUMAN; PATIENT MONITORING; PREVALENCE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; VASCULITIS; VIRUS REACTIVATION;

EID: 84874013235     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0319-1     Document Type: Article

References (53)

1. Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol. 2012;8:348-57.
2. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486-500.
3. Lok ASF, McMahon BJ. AASLD practice guidelines. Chronic Hepatitis B: Update 2009. Accessed at www.aasld.org. Accessed 18 Dec 2012.
4. Vassilopoulos D, Manolakopoulos S. Rheumatic manifestations of hepatitis. Curr Opin Rheumatol. 2010;22:91-6.
5. Varache S, Narbonne V, Jousse-Joulin S, et al. Is routine viral screening useful in patients with recent-onset polyarthritis of a duration of at least 6 weeks? Results from a nationwide longitudinal prospective cohort study. Arthritis Care Res (Hoboken). 2011;63:1565-70.
6. Tan J, Zhou J, Zhao P, et al. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31:1169-75.
7. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49: S156-65.
8. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy: Analysis of 257 Cases. Medicine (Baltimore). 2011;90:359-71.
9. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Longterm safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010;69:1352-5.
10. Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170-80.
11. Mendez-Navarro J, Corey KE, Zheng H, et al. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int. 2011;31:330-9.
12. Chen XQ, Peng JW, Lin GN, et al. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol. 2012;29:1237-41.
13. Pyrpasopoulou A, Douma S, Vassiliadis T, et al. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int. 2011;31:403-4.
14. Mitroulis I, Hatzara C, Kandili A, et al. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2013;72:308-10.
15. Kim PS, Ho GY, Prete PE, et al. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken). 2012;64:1265-8.
16. Said ZN. An overview of occult hepatitis B virus infection. World J Gastroenterol. 2011;17:1927-38.
17. Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. J Am Acad Dermatol. 2012;67:1349-61.
18. Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med. 2011;154:319-28.
19. Giardina AR, Ferraro D, Ciccia F, et al. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study. Clin Exp Rheumatol. 2013;31:25-30.
20. Urata Y, Uesato R, Tanaka D, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011;21:16-23.
21. Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological diseasemodifying antirheumatic drugs. Mod Rheumatol. 2011;21:621-7.
22. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2013;31:118-21.
23. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185.
24. Lok AS, Ward JW, Perrillo RP, et al. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med. 2012;156:743-5.
25. Stine JG, Khokhar OS, Charalambopoulos J, et al. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care Res (Hoboken). 2010;62:704-11.
26. Vaughn BP, Doherty GA, Gautam S, et al. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis. 2012;18:1057-63.
27. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74.
28. Smith BD, Morgan RL, Beckett GA, et al. Hepatitis C virus testing of persons born during 1945 to 1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157:817-22.
29. Vassilopoulos D, Calabrese LH. Rheumatic manifestations of hepatitis C infection. Curr Rheumatol Rep. 2003;5:200-4.
30. Rosner I, Rozenbaum M, Toubi E, et al. The case for hepatitis C arthritis. Semin Arthritis Rheum. 2004;33:375-87.
31. Ogdie A, Schumacher Jr HR, Dai L, et al. Synovial biopsy findings in arthritis associated with hepatitis C virus infection. J Rheumatol. 2010;37:1361-3.
32. Zuckerman E, Keren D, Rozenbaum M, et al. Hepatitis C virusrelated arthritis: characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol. 2000;18:579-84.
33. Ramos-Casals M, Stone JH, Cid MC, et al. The cryoglobulinaemias. Lancet. 2012;379:348-60.
34. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33:355-74.
35. Saadoun D, Asselah T, Resche-Rigon M, et al. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. Hepatology. 2006;43:1337-45.
36. Kayali Z, Buckwold VE, Zimmerman B, et al. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology. 2002;36:978-85.
37. Terrier B, Semoun O, Saadoun D, et al. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011;63:1748-57.
38. Mazzaro C, Zorat F, Caizzi M, et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol. 2005;42:632-8.
39. Joshi S, Kuczynski M, Heathcote EJ. Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulimia. Dig Dis Sci. 2007;52:2410-7.
40. Saadoun D, Resche RM, Sene D, et al. Rituximab plus Peginterferon- alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116:326-34.
41. Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferonalpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116:343-53.
42. Clinical EASL. Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-64.
43. Vassilopoulos D, Calabrese LH. Hepatitis C virus infection and vasculitis. Implications of antiviral and immunosuppressive therapies. Arthritis Rheum. 2002;46:585-97.
44. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-44.
45. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216-24.
46. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843-53.
47. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:835-42.
48. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-84.
49. Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012;71 Suppl 2:i2-45.
50. Brunasso AM, Puntoni M, Gulia A, et al. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford). 2011;50:1700-11.
51. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625-39.
52. Terrier B, Saadoun D, Sene D, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum. 2009;60:2531-40.
53. Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood. 2010;116:335-42.